Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Bristol-Myers Squibb | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Bristol-Myers Squibb

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Bristol-Myers Squibb
 
4Q Revenues: $5.4 billion (+33%)

4Q Loss: $89 million (loss of $134 million in 4Q2006)

FY Revenues: $19.3 billion (+12%)

FY Earnings: $2.2 billion (+37%)

Comments: Worldwide pharmaceutical sales increased 39% to $4.4 billion in the quarter. U.S. pharma sales were up 65% to $2.5 billion due to increased Plavix sales, as well as growth of Abilify, Reyataz, the Sustiva Franchise and Erbitux, and sales of newer products Orencia, Baraclude, Sprycel and Ixempra. Plavix sales increased 177% to $1.4 billion in the quarter (growth is skewed because of the temporary Plavix generic issues in 4Q06). Abilify sales were up 28% to $462 million. Reyataz sales increased 31% to $334 million in the quarter. Sustiva sales increased 17% to $260 million. Erbitux sales increased 11% to $185 million in the quarter. 4Q07 R&D expenses were $1.1 million (+42%) reflecting the in-process R&D charge of $230 million related to the Adnexus acquisition. 4Q07 results also include charges of $292 million associated with the company’s restructuring initiative and an impairment charge of $275 million.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters